HIGHLIGHTS
- who: Suli Zhang from the (BARC), India University of Florence, Italy have published the research work: Local therapy treatment conditions for oligometastatic non-small cell lung cancer, in the Journal: (JOURNAL)
- what: PFS and OS benefit have been shown after ablation therapy for OM-NSCLC.
- how: The data showed that PFS was significantly improved in the LCT group with PFS of 11.9 months and 3.9 months in study and control groups respectively after a median follow-up of 12 months (P=0.0054). The results showed that SABR was associated with . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.